DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
ZYH-7
Prediction of ZYH 7 below……..If it does not match then ZYH 7 will be a very close structure
1014989-63-9
Acetic acid, 2-[2-methyl-4-[1-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]- 5-thiazolyl]methoxy]imino]ethyl]phenoxy]-
Zydus-Cadila is developing ZYH-7, a PPAR alpha modulator for the potential treatment of dyslipidemia .
By January 2012, phase II trials had begun ; in January 2014, the drug was still listed as being in phase II development
By January 2012 phase II trials had begun for Diabetes type 2 Lipoprotein disorders
Obesity
In August 2007, an IND was filed , and by March 2008, a phase I trial was underway ; by April 2011, the trial had been completed
| Zydus Cadila has filed an Investigational New Drug (NID) application for seeking DCGI’s permission for conducting clinical trials for its New Molecular Entity (NME) ZYH7. |
 |
| According to a company release, it claims that ZYH7 is a novel drug candidate for treating dyslipidemia and metabolic disorders. The company inform that ZYH7 had been conceptualised and developed by its scientists from Zydus Research Centre. |
| The company has its in-house research centre and it had recently concluded pre-clinical studies on ZYH7, which have reported interesting and encouraging finding which indicate a novel molecule to treat dyslipidemia and associated metabolic disorders. |
| Commenting on the new development, Pankaj Patel, chairman and managing director, Zydus Cadila said, “We have been building a promising pipeline of new molecular entities at the Zydus Research Centre and ZYH7 is an important step in this direction”. |
| Starting with its first IND filing in 2005, Zydus today has four INDs in various stages of clinical trials. NME – ZYH1 for treating dyslipidemia and ZYI1 for treating pain and inflammation are undergoing Phase II trials. ZYH2 for treating diabetes and the novel CB-1 antagonist, ZYO1 for treating obesity, are undergoing Phase I trials. |
| Diabetes, a worldwide health problem, affects more than 150 million people, a number expected to double to 300 million by 2025. People with diabetes are at especially high risk for dyslipidemia, particularly high triglyceride levels and low HDL levels. |
| Dyslipidemia is also a key independent risk factor for cardiovascular disease (CVD), which is the largest therapeutic segment in the world pharmaceutical market. |
| With an increasing correlation between several endocrine and metabolic disorders, there has been considerable emphasis in recent times on metabolic syndrome. The metabolic components of cardiovascular disease, diabetes and obesity, are linked in numerous ways with each having an impact on the other. |
| For instance, it is also well known that patients with Type 2 diabetes have a two to four-fold excess risk of coronary heart disease and that these patients very often have increased cardiovascular risk factors even before the onset of their diabetes. |
Dyslipidemia is an abnormal amount of lipids (e.g. cholesterol and/or fat) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.
| Dyslipidemia | |
|---|---|
| Classification and external resources | |
| ICD–10 | E78 |
| ICD–9 | 272 |
| DiseasesDB | 33452 |
| MeSH | D050171 |
Classification
Physicians and basic researchers classify dyslipidemias in two distinct ways:
- Phenotype, or the presentation in the body (including the specific type of lipid that is increased)
- Etiology, or the reason for the condition (genetic, or secondary to another condition). This classification can be problematic, because most conditions involve the intersection of genetics and lifestyle issues. However, there are a few well-defined genetic conditions that are usually easy to identify.
Fredrickson Classification:[1]
For more a detailed version, see Hyperlipidemia#Classification.
| Phenotype | I | IIa | IIb | III | IV | V |
|---|---|---|---|---|---|---|
| Elevated Lipoprotein | Chylomicron | LDL | LDL and VLDL | IDL | VLDL | VLDL and chylomicrons |
WO 2008035359
https://www.google.com/patents/WO2008035359A2?cl=en
Scheme 1 below which comprises:
Scheme 2 below which comprises
| Citing Patent | Filing date | Publication date | Applicant | Title |
|---|---|---|---|---|
| WO2009021740A2 | Aug 14, 2008 | Feb 19, 2009 | Sanofis Aventis | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
| WO2010049946A2 * | Oct 22, 2009 | May 6, 2010 | Cadila Healthcare Limited | Thyroid receptor ligands |
| WO2010084512A1 * | Dec 22, 2009 | Jul 29, 2010 | Cadila Healthcare Limited | Novel oxime derivatives |
| WO2010110479A1 * | Mar 24, 2010 | Sep 30, 2010 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor |
| WO2011157827A1 | Jun 17, 2011 | Dec 22, 2011 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| WO2013037390A1 | Sep 12, 2011 | Mar 21, 2013 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2014192023A1 * | May 20, 2014 | Dec 4, 2014 | Cadila Healthcare Limited | Novel compounds suitable for the treatment of dyslipidemia |
| EP2567959A1 | Sep 12, 2011 | Mar 13, 2013 | Sanofi | 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8742117 | Dec 22, 2009 | Jun 3, 2014 | Cadila Healthcare Limited | Oxime derivatives |
| US8822414 * | Dec 26, 2011 | Sep 2, 2014 | Cadila Healthcare Limited | Heterocyclic compounds suitable for the treatment of dyslipidemia |
………….
PARIS
New Drug Approvals 